mTOR Signaling in Immune Cell Function
Placeholder: mTOR complexes shape T-cell metabolism and differentiation.
- mTORC1/2: Pathway (Placeholder short note)
- T-cells: Key cells (Placeholder short note)
- mTOR inhibitor: Drug class (Placeholder short note)
- 1970s: Discovery era (Placeholder short note)
How mTOR shapes immune cell activation
Placeholder: mTOR integrates nutrient and growth signals for immune cells.
Infection Risk at Higher Rapamycin Doses
Placeholder: transplant-level dosing raises susceptibility to infection.
- Dose intensity: Risk driver (Placeholder short note)
- Opportunistic infection: Common issue (Placeholder short note)
- Transplant rejection: Typical use (Placeholder short note)
- Benefit vs risk: Trade-off (Placeholder short note)
Why higher doses raise infection susceptibility
Placeholder: stronger immune suppression reduces pathogen clearance ability.
Low-Dose Longevity vs Transplant-Dose Immunosuppression
Placeholder: dose context determines whether effects favor longevity or rejection control.
- Healthspan: Low-dose goal (Placeholder short note)
- Graft survival: High-dose goal (Placeholder short note)
- Minimal: Low-dose risk (Placeholder short note)
- Substantial: High-dose risk (Placeholder short note)
Comparing longevity and transplant dosing regimens
Placeholder: dosing strategy shifts the balance of benefit and suppression.
Monitoring for Infection Signs During Therapy
Placeholder: routine checks help detect infection before it worsens.
- Blood counts: Monitor (Placeholder short note)
- Fever screening: Monitor (Placeholder short note)
- Regular visits: Frequency (Placeholder short note)
- Early detection: Goal (Placeholder short note)
What clinical monitoring looks for
Placeholder: monitoring tracks infection markers and immune status regularly.
Adjusting Dose for Risk-Benefit Balance
Placeholder: dose titration aims to preserve benefit while limiting risk.
- Titration: Approach (Placeholder short note)
- Risk signs: Trigger (Placeholder short note)
- Balanced regimen: Outcome (Placeholder short note)
- Clinician: Decision-maker (Placeholder short note)
How dose is adjusted for individual risk
Placeholder: adjustments weigh individual infection risk against therapy goals.
Placeholder: individualized dosing balances immunosuppressive benefit and infection risk.